



SPD

FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

Established in 1859

SUITE 401L - 1801 K STREET, NW
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LA SALLE STREET, CHICAGO, ILLINOIS 60603-3406

TELEPHONE (312) 577-7000

CALIFORNIA OFFICE

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7708

TELEPHONE (858) 552-1311

COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302

TELEPHONE (303) 402-6966

June 22, 2004

MORGAN L. FITCH
FRANCIS A. EVEN
JULIUS TABIN
JOHN F. FLANNERY
ROBERT B. JONES
JAMES J. SCHUMANN
JAMES J. HAMILL
TIMOTHY E. LEVSTIK
JOSEPH E. SHIPLEY
KENNETH H. SAMPLES
PHILIP T. PETTI
JOSEPH T. NABOR
STEVEN C. SCHROER
RICHARD A. KABA*
KARL R. FINK
MARK W. HETZLER
TIMOTHY P. MALONEY
JAMES P. KRUEGER
STEPHEN S. FAVAKEH
RICHARD E. WAWRZYNIAK
STEVEN G. PARMELEE
THOMAS F. LEBENS
BRUCE R. MANSFIELD
KENDREW H. COLTON*
G. PAUL EDGELL*
MICHAEL A. SANZO*
SCOTT A. MENGHINI
NORMAN N. KUNITZ*
RUDY KRATZ
RAMON R. HOCH*

EDWARD E. CLAIR
JON A. BIRMINGHAM
JOHN E. LYHUS
STEVEN M. FREELAND
DONNA E. BECKER
MICHAEL G. VRANICAR
BRIAN S. CLISE
MARTIN R. BADER
DEREK L. PRESTIN
MARK A. BORSOS
DAVID R. JAGLOWSKI
TIMOTHY R. BAUMANN
JEFFREY A. CHELSTROM
NICHOLAS T. PETERS
KENNETH A. PLOCHINSKI
MEGAN J. REDMOND

PATENT AGENTS

ERIC J. WHITESELL
LILIA I. SAFONOV

OF COUNSEL

GEORGE W. SPELLMIRE, JR.
LISA M. SOMMER
GEORGE H. SPENCER, P.C.*

TECHNICAL ADVISOR

JOHN M. BRONK, PH.D.

*ADMITTED TO D.C. BAR; D.C. PRACTICE OF
ALL OTHERS LIMITED TO FEDERAL COURTS
AND AGENCIES

Commissioner of Patents
U.S. Patent and Trademark Office
220 20th Street S.
Customer Window, **MS Amendment**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Re: Supplemental Information Disclosure Statement
Appl. No.: 10/612,338
Filed: July 3, 2003
Title: **Compositions and Methods Involving the
Combination of a Thromboxane A2 Receptor
Antagonist and an Inhibitor of Cyclooxygenase-2**
Inventor(s): Brunner, Hans R.
Atty. Dkt.: 7571/80526

Sir:

The following documents are being forwarded for appropriate action by the U.S. Patent and Trademark Office:

1. Supplemental Information Disclosure Statement;
2. PTO Form-1449, List of References Cited by Applicant;
3. References A1-A6, B1-B6 and C1-C15; and
4. Return postcard.

Commissioner of Patents
June 22, 2004
Page 2

Applicant does not believe that any fee is due for the filing of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency with respect to this filing and any other fee required in connection with the present case, or credit any overpayment, to our Deposit Account No. 06-1135 under Order No. 7571/80526.

It is respectfully requested that the enclosed postcard be stamped with the date the enclosed documents are received by the PTO and that it be returned as soon as possible.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

A handwritten signature in black ink that reads "Michael A. Sanzo". The signature is written in a cursive, flowing style.

Michael A. Sanzo
Attorney for Applicant
Registration No. 36,912

MAS:ct
Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Brunner, Hans R.

Appl. No.: 10/612,338

Filed: July 3, 2003

For: **Compositions and Methods Involving
the Combination of a Thromboxane
A2 Receptor Antagonist and an Inhibitor
of Cyclooxygenase-2**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7571/80526

Supplemental Information Disclosure Statement

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, **MS Amendment**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Submitted herewith is a listing of documents known to Applicant and/or his attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed documents are also enclosed.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned attorney submits the following concise explanation of the relevance of the non-English language document cited on the accompanying form:

Reference B2, published international patent application WO 92/02494, describes cyclopentene thromboxane-A2 antagonists that can be used for treating cardiovascular disorders, migraine, allergies and other conditions. The compounds have also been found to have a cyto-protective effect. An English language abstract corresponding to this document is cited on the accompanying list of references as document C14.

Reference B4, published international patent application WO 92/19270, describes calcium/serotonin and thromboxane 2 receptor antagonists. Drug compositions containing these antagonists are useful in treating coronary heart conditions and arterial occlusion disorders by inhibiting thrombosis and vasospasticity. An English language abstract corresponding to this document is cited on the accompanying list of references as document C15.

Applicant does not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.


Applicant does not believe any fee is due for the submission of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7571/80526.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo
Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicant

Date: June 23, 2004
1801 K Street, N.W., Suite 401L
Washington, DC 20006-1201
Phone: (202) 419-7013

 <p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>				Atty. Docket No.: 7571/80526		Appl. No.: 10/612,338			
				Applicant(s) Brunner, Hans R.					
				Filing Date: July 3, 2003		Group: to be assigned			
U.S. PATENT DOCUMENTS									
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate		
	A 1	5,605,917	Feb. 25, 1997	Ogletree	514	365	Dec. 22, 1994		
	A 2	5,872,145	Feb. 16, 1999	Plachetka	514	415	Aug. 14, 1997		
	A 3	6,060,499	May 9, 2000	Plachetka	514	415	Sep. 11, 1998		
	A 4	6,077,539	Jun. 20, 2000	Plachetka, <i>et al.</i>	424	474	Nov. 10, 1997		
	A 5	6,479,551 B1	Nov. 12, 2002	Plachetka, <i>et al.</i>	514	619	Mar. 3, 2000		
	A 6	6,586,458 B1	Jul. 1, 2003	Plachetka	514	415	Apr. 27, 2000		
	A 7								
	A 8								
	A 9								
	A 10								
	A 11								
	A 12								
	A 13								
	A 14								
	A 15								
	A 16								
	A 17								
	A 18								
	A 19								
	A 20								
	A 21								
	A 22								
	A 23								
	A 24								
	A 25								
	A 26								
	A 27								
Examiner				Date Considered					

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>				Atty. Docket No.: 7571/80526		Appl. No.: 10/612,338		
				Applicant(s) Brunner, Hans R.				
				Filing Date: July 3, 2003		Group: to be assigned		
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Country	Class	Subclass	Abst./Trans.	
							Yes	No
	B 1	WO 91/13062	Sep. 5, 1991	WIPO	C07D	233/61		
	B 2	WO 92/02494	Feb. 20, 1992	WIPO	C07C	405/00	X	
	B 3	WO 92/19182	Nov. 12, 1992	WIPO	A61F	2/02		
	B 4	WO 92/19270	Nov. 12, 1992	WIPO	A61K	45/06	X	
	B 5	WO 99/45905	Sep. 16, 1999	WIPO	A61K	31/00		
	B 6	GB 2 038 821	Jul. 30, 1980	United Kingdom	C07D	233/60		
	B 7							
	B 8							
	B 9							
	B 10							
	B 11							
	B 12							
	B 13							
	B 14							
	B 15							
	B 16							
	B 17							
	B 18							
	B 19							
	B 20							
	B 21							
	B 22							
	B 23							
	B 24							
	B 25							
	B 26							
	B 27							
Examiner				Date Considered				

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No.: 7571/80526	Appl. No.: 10/612,338
		Applicant(s) Brunner, Hans R.	
		Filing Date: July 3, 2003	Group: to be assigned
Examiner Initial	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C 1	BEASLEY, <i>et al.</i> , "Effect of a Thromboxane Receptor Antagonist on PGD ₂ and Allergen-Induced Bronchoconstriction," <i>J. Appl. Physiol.</i> 66:1685-1693 (1989).	
	C 2	BELLEVANCE, <i>et al.</i> , "A Comparative Study of Naproxen Sodium, Pizotyline and Placebo in Migraine Prophylaxis," <i>Headache</i> 30:710-715 (1990).	
	C 3	CADY, <i>et al.</i> , "Treatment of Acute Migraine with Subcutaneous Sumatriptan," <i>JAMA</i> 265:2831-2835 (1991).	
	C 4	DeMAIS, <i>et al.</i> , "Thromboxane A ₂ Receptor Antagonists. Synthesis and Activities of Phenylsulfonamido Derivatives," <i>Eur. J. Med. Chem.</i> 26:821-827 (1991).	
	C 5	DIAMOND, <i>et al.</i> , "Long-Term Study of Propranolol in the Treatment of Migraine," <i>Headache</i> 22:268-271 (1982).	
	C 6	FITZGERALD, <i>et al.</i> , "Role of Thrombin and Thromboxane A ₂ in Reocclusion Following Coronary Thrombolysis with Tissue-Type Plasminogen Activator," <i>Proc. Natl. Acad. Sci. USA</i> 86:7585-7589 (1989).	
	C 7	HIRATA, <i>et al.</i> , "Roles of Platelet-Activating Factor, Thromboxane A ₂ , ADP and Thrombin in Thrombogenesis in the Guinea Pig," <i>Eur. J. Pharmacol.</i> 231:421-425 (1993).	
	C 8	KURITZKY, "Sodium Valproate in the Prophylactic Treatment of Migraine: a Double-Blind Study Versus Placebo," <i>Cephalalgia</i> 12:81-84 (1992).	
	C 9	LUMLEY, <i>et al.</i> , "The Effects of GR32191, a New Thromboxane Receptor Blocking Drug, on Platelets and Vascular Smooth Muscle in Vitro," <i>Thrombosis and Haemostasis</i> 58:261 (1987).	
	C 10	MYOU, <i>et al.</i> , "Inhibitory Effect of a Selective Thromboxane Synthetase Inhibitor, OKY-046, on Acetaldehyde-Induced Bronchoconstriction in Asthmatic Patients," <i>Chest</i> 106:1414-1418 (1994).	
	C 11	TEMPLETON, <i>et al.</i> , "The Role of Endogenous Thromboxane in Contractions to U46619, Oxygen, 5-HT and 5-CT in the Human Isolated Umbilical Artery," <i>Br. J. Pharmacol.</i> 103:1079-1084 (1991).	
	C 12	YOUNG, "Appropriate Use of Ergotamine Tartrate and Dihydroergotamine in the Treatment of Migraine: Current Perspectives," <i>Headache</i> 37(Supp. 1):S42-S45 (1997).	
	C 13	ZIEGLER, <i>et al.</i> , "Migraine Prophylaxis. A Comparison of Propranolol and Amitriptyline," <i>Arch. Neurol.</i> 44:486-489 (1987).	
	C 14	English language abstract for WO 92/02494, Reference B2 above.	
	C 15	English language abstract for WO 92/19270, Reference B4 above.	
	C 16		
	C 17		
	C 18		
	C 19		
Examiner		Date Considered	